When did Phibro Animal Health report Q2 2026 earnings?

Phibro Animal Health (PAHC) reported Q2 2026 earnings on February 4, 2026 after market close.

What were Phibro Animal Health's Q2 2026 revenue and EPS?

Phibro Animal Health reported revenue of $373.9M and eps of $0.87 for Q2 2026.

Did Phibro Animal Health beat estimates in Q2 2026?

Revenue beat the consensus estimate of $355.6M by $18.3M. EPS beat the consensus estimate of $0.69 by $0.18.

How did Phibro Animal Health's Q2 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 20.9% from $309.3M a year earlier and eps grew 61.1% from $0.54.

Where can I find Phibro Animal Health's Q2 2026 SEC filings?

You can read the 8-K earnings release (0001104659-26-009739) and the 10-Q periodic report (0001104659-26-010317) directly on SEC EDGAR. The filing index links above go to sec.gov.

Phibro Animal Health PAHC Q2 2026 earnings

Reported February 4, 2026 · After market close

Revenue$373.9MBeat by $18.3M

EPS$0.87Beat by $0.18

Revenue estimate$355.6M

EPS estimate$0.69

Next report

Aug 26, 2026 (In 4 weeks)

Revenue estimate$381.2M

EPS estimate$0.72

Financials

Q2 2026

Income statement

See full

Revenue$373.9M+20.9%

Gross profit$132.7M+30.2%

Operating income$50.3M+97.1%

Net income$27.5M+762%

EPS (diluted)$0.67+738%

Balance sheet

See full

Cash & equivalents$55.5M-17.3%

Total debt$29.6M+22.0%

Total equity$332.4M+34.7%

Total assets$1.4B+9.3%

Cash flow

See full

Operating cash flow$19.4M+529%

CapEx$11.1M+41.9%

Free cash flow$8.3M+274%

Valuation & ratios

Valuation

as of 12/31/25

See full

Market cap$1.51B+78.0%

Enterprise value$1.49B+84.3%

P/E16.4×-27.6×

P/S1×+0.3×

Profitability

See full

Gross margin31.9%+0.1pp

Operating margin11.5%+4.2pp

Net margin6.3%+4.5pp

FCF margin3.2%+1.8pp

Returns & leverage

See full

Return on equity31.8%+24.3pp

Debt / equity0.1×0.0×

Current ratio3.1×-0.1×

Segments

By product

See full

Medicated Feed Additives And Others$202.1M+34.4%

Mineral Nutrition$68.9M+9.0%

Nutritional Specialties$50.2M+9.4%

Vaccines$37.6M+13.5%

Performance Products$15.0M-9.7%

By segment

See full

Animal Health$290.0M+26.4%

Mineral Nutrition$68.9M+9.0%

Performance Products$15.0M-9.7%

By geography

See full

Latin America And Canada$87.6M+20.5%

EMEA$44.8M+37.4%

Asia Pacific$19.8M+1.1%

Versus estimates

Revenue

Q3 2026$383.5MBeat by $16.5M

Q2 2026$373.9MBeat by $18.3M

Q1 2026$363.9MBeat by $18.5M Q4 2025$378.7MBeat by $16.3M Q3 2025$347.8MMiss by $14.4M Q2 2025$309.3MMiss by $37.7M

Diluted EPS

Q3 2026$0.76Beat by $0.04

Q2 2026$0.87Beat by $0.18

Q1 2026$0.73Beat by $0.14 Q4 2025$0.57Beat by $0.05 Q3 2025$0.63Beat by $0.11 Q2 2025$0.54Beat by $0.14

Ask the moment Phibro Animal Health reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Phibro Animal Health report Q2 2026 earnings?: Phibro Animal Health (PAHC) reported Q2 2026 earnings on February 4, 2026 after market close.
What were Phibro Animal Health's Q2 2026 revenue and EPS?: Phibro Animal Health reported revenue of $373.9M and eps of $0.87 for Q2 2026.
Did Phibro Animal Health beat estimates in Q2 2026?: Revenue beat the consensus estimate of $355.6M by $18.3M. EPS beat the consensus estimate of $0.69 by $0.18.
How did Phibro Animal Health's Q2 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 20.9% from $309.3M a year earlier and eps grew 61.1% from $0.54.
Where can I find Phibro Animal Health's Q2 2026 SEC filings?: You can read the 8-K earnings release (0001104659-26-009739) and the 10-Q periodic report (0001104659-26-010317) directly on SEC EDGAR. The filing index links above go to sec.gov.